HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ibritumomab tiuxetan (Zevalin)

90Y-labeled anti-CD20 monoclonal antibody for radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
Also Known As:
Zevalin; IDEC-129; IDEC-Y2B8; IDEC-Y2B8 IDEC-129; yttrium-90-ibritumomab tiuxetan
Networked: 275 relevant articles (35 outcomes, 83 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Witzig, Thomas E: 20 articles (07/2013 - 02/2002)
2. Gordon, Leo I: 20 articles (10/2009 - 02/2002)
3. Emmanouilides, Christos: 15 articles (10/2009 - 02/2002)
4. Wiseman, Gregory A: 13 articles (07/2013 - 02/2002)
5. White, Christine A: 13 articles (04/2009 - 02/2002)
6. Molina, Arturo: 12 articles (04/2009 - 06/2004)
7. Schilder, Russell J: 9 articles (09/2007 - 06/2002)
8. Zinzani, Pier Luigi: 8 articles (11/2019 - 07/2007)
9. Grillo-López, Antonio J: 8 articles (02/2005 - 02/2002)
10. Morschhauser, Franck: 7 articles (12/2014 - 07/2007)

Related Diseases

1. Non-Hodgkin Lymphoma (Lymphosarcoma)
2. Lymphoma (Lymphomas)
3. Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
4. B-Cell Lymphoma (Lymphoma, B Cell)
5. Pathologic Complete Response

Related Drugs and Biologics

1. ibritumomab tiuxetan (Zevalin)
2. Yttrium-90
3. Rituximab (Mabthera)
4. Melphalan (Alkeran)
5. Yttrium
6. Etoposide (VP 16)
7. fludarabine
8. Cytarabine (Cytosar-U)
9. Carmustine (FIVB)
10. Cyclophosphamide (Cytoxan)

Related Therapies and Procedures

1. Radioimmunotherapy
2. Therapeutics
3. Drug Therapy (Chemotherapy)
4. Stem Cell Transplantation
5. Radiotherapy